Fagron Pays $22 Million to Settle DOJ Allegations Against Subsidiaries

Drug Industry Daily
A A
Drug compounder Fagron has agreed to pay $22 million to settle claims against three of its subsidiaries.

To View This Article:

Login

Subscribe To Drug Industry Daily